Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Product approval in US

7 Feb 2008 07:00

ViaLogy PLC07 February 2008 VIALOGY SPM product successfully tested and approved by US National Incident Management System London, 7 February, 2008: ViaLogy PLC (LSE: VIY), a leading innovator ofreal-time network-centric signal processing platforms, announces that itsproduct SPMTM (Sensor Policy ManagerTM), for sensor interoperability andintegration, has received unqualified approval from America's National IncidentManagement System Support Center (NIMS SC), a division of The Department ofHomeland Security's (DHS) Federal Emergency Management Agency (FEMA). NIMSawarded SPM top marks in all tested categories. NIMS has been established by the US government to deal with national emergencysituations, including terrorist attacks. It enables responders from differentjurisdictions and disciplines to work together to respond to natural disastersand emergencies, including acts of terrorism. Benefits include a unifiedapproach to incident management; standard command and management structures; andemphasis on preparedness, mutual aid and resource management. Key to any emergency situation response is the ability of all the differentsensors involved to integrate information and prioritise alerts. ViaLogy's SPMis designed specifically to enable this to happen seamlessly and immediately. Inrecent weeks NIMS engineers have been subjecting the product to extensive andrigorous testing. They have determined that SPM meets all its requiredstandards. "The product is consistent with the concepts and principles of NIMS,"concludes the Evaluation Report. "It is applicable to all 15 Emergency SupportFunctions, all six hazard groups, and to a multi-jurisdictional response." Ineach case the tests marked SPM five out of five. In addition, the report praisedthe speed at which SPM could be incorporated in any sensor and the fact that ittakes just 20 hours to fully train an SPM operator. "We are absolutely delighted with the NIMS validation," said Robert W. Dean,President and CEO of ViaLogy. "Our SPM product is designed to enable aco-ordinated proactive response by all the emergency services involved indealing with an emergency incident. Quite simply, it will help to save lives. "Most importantly, the system is sensor agnostic so it can create instantcommunication between a wide variety of sensors used in a range of safety,security and emergency response applications." ViaLogy is also participating in additional validation demonstrations with anumber of manufacturers involved in producing and integrating commercialsecurity systems. ends ViaLogyRobert W Dean, President/CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)Terry Bond, Chairman - UK & Europe +44 (0)1235 834734 Nominated Advisor (Seymour Pierce)Mark Percy +44 (0)20 7107 8000 PR Consultants - Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications and sensor fusion. ViaLogy is currentlydeploying and designing computational systems, powered by its patentedtechnologies, for applications in life sciences, public safety and security,surveillance, defense and geoseismology. Vialogy focuses on market drivenproblems where automation, timeliness, quality and reliability of informationprocessing are essential. ViaLogy's core competency incorporates rapidly andaccurately detecting weak signals buried in high noise background and clutter.This technology can be employed to solve problems involving sensor integrationand information overload challenges involving video, telephony and controlsensors, as well as for enhancement of numerous signal processing applications.For more information, visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.